BioLineRx's antipsychotic positive in Phase IIb trial
This article was originally published in Scrip
Executive Summary
BioLineRx's lead drug candidate, the antipsychotic BL-1020 (GABA plus perphenazine), improved schizophrenia symptoms compared with placebo and improved cognitive function compared with a mainstay of treatment, show top-line Phase IIb trial results.